Larsucosterol for the Treatment of Alcohol-Associated Hepatitis

20257 citationsJournal Article

Authors

Mitchell Shiffman · Bon Secours Liver Institute of Richmond

Ben L. Da · Northwell Health

Aparna Goel · Stanford University

Allison J. Kwong · Palo Alto University

Lance L. Stein · Piedmont HealthCare

Christophe Moreno · Université Libre de Bruxelles

Amanda Nicoll ·

Abstract

The trial did not meet the primary end point of showing a beneficial effect of larsucosterol on 90-day mortality or LT in patients with severe AH. Equipoise has been established for a further trial of larsucosterol on AH survival. (The trial was funded by the DURECT Corporation; its ClinicalTrials.gov number is NCT04563026.).

Topics & Keywords

Liver Disease Diagnosis and Treatment Alcohol Consumption and Health Effects Liver Disease and Transplantation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: NEJM Evidence

Volume 4, Issue 2, pp. EVIDoa2400243-EVIDoa2400243

DOI: 10.1056/evidoa2400243

Field-Weighted Citation Impact: 12.41